Pre-Open Stock Movers 12/01: (BSTG) (BLUE) (CLC) Higher; (ARDM) (HTBX) (PTN) Lower (more...)

December 1, 2016 9:28 AM EST

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Today's Pre-Open Stock Movers

Aradigm Corporation (Nasdaq: ARDM) 61.8% LOWER; announced top-line results from its two Phase 3 clinical trials (ORBIT-3 and ORBIT-4) evaluating the safety and efficacy of Pulmaquin®, the Companys investigational proprietary formulation of once daily ciprofloxacin for inhalation, in patients with non-cystic fibrosis bronchiectasis (non-CF BE) with chronic lung infections with Pseudomonas aeruginosa (P. aeruginosa).

Heat Biologics (Nasdaq: HTBX) 59.9% LOWER; announced that it presented topline data from its 94-patient Phase II trial evaluating HS-410 (vesigenurtacel-L) in combination with standard of care, Bacillus Calmette-Guérin (BCG), or as a monotherapy, for the treatment of non-muscle invasive bladder cancer..

Biostage, Inc. (Nasdaq: BSTG) 56.3% HIGHER; announced that its Cellspan Esophageal Implant was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) to restore the structure and function of the esophagus subsequent to esophageal damage due to cancer, injury or congenital abnormalities.

Palatin Technologies, Inc (NYSE: PTN) 28.4% LOWER; announced the pricing of an underwritten public offering of 25,384,616 shares of its common stock and warrants to purchase 12,692,310 shares of its common stock for anticipated gross proceeds of $16.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Palatin. The shares of common stock and warrants will be offered as Series A Units, with each Series A Unit consisting of one share of common stock and a Series J warrant to purchase 0.50 of a share of common stock, and will be priced at $0.65 per unit.

bluebird bio, Inc. (Nasdaq: BLUE) 22.3% HIGHER; announced that interim data from its ongoing Phase 1 clinical study of bb2121, the companys investigational anti-BCMA CAR T cell product candidate in patients with relapsed/refractory multiple myeloma, will be presented on Thursday, December 1, 2016 at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany. bluebird bio is developing bb2121 in collaboration with Celgene Corporation.

Express (NYSE: EXPR) 17.3% LOWER; reported Q3 EPS of $0.15, $0.02 better than the analyst estimate of $0.13. Revenue for the quarter came in at $506.1 million versus the consensus estimate of $498.75 million. E-commerce sales increased 15% to $96.3 million. Comps fell 8 percent, versus a drop of 9.9 percent expected by the Street. GUIDANCE: The company sees Q4 EPS of $0.26 - $0.30, versus $0.55 expected. Express sees FY2016 EPS of $0.78-$0.82, versus the consensus of $1.05.

Tilly's, Inc. (NYSE: TLYS) 17% HIGHER; reported Q3 EPS of $0.22, $0.11 better than the analyst estimate of $0.11. Revenue for the quarter came in at $152.1 million versus the consensus estimate of $143 million. GUIDANCE: Tilly's, Inc. sees Q4 2016 EPS of $0.15-$0.20, versus the consensus of $0.18.

Christopher & Banks (NYSE: CBK) 16.3% HIGHER; reported Q3 EPS of $0.09, $0.04 better than the analyst estimate of $0.05. Revenue for the quarter came in at $106.7 million versus the consensus estimate of $104.66 million. Comparable sales increased 4.5% compared to a 6.7% decrease in the same period last year. Gross margin rate increased 95 basis points to 36.8%, as compared to last year’s third quarter. GUIDANCE: Christopher & Banks sees Q4 2016 revenue of $93-97 million, versus the consensus of $99.6 million.

CLARCOR Inc. (NYSE: CLC) 16% HIGHER; Parker Hannifin Corporation (NYSE: PH) and CLARCOR Inc. (NYSE: CLC) announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt.

Guess? (NYSE: GES) 13.5% LOWER; reported Q3 EPS of $0.11, $0.03 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $536.3 million versus the consensus estimate of $548.37 million. GUIDANCE: Guess? sees Q4 2017 EPS of $0.40-$0.50. Guess? sees FY2017 EPS of $0.42-$0.52.

FuelCell Energy (NASDAQ: FCEL) 11% LOWER; to Conduct Corp. Restructuring; Prelim. Q4, FY16 Revenue Light of Views

Skechers USA (NYSE: SKX) 7.6% HIGHER; CEO, Robert Greenberg, bought 500,000 share from 11/28-11/29 at prices from $21.18-$21.75. Also upgrade at Buckingham.

Semtech (NASDAQ: SMTC) 6.4% HIGHER; reported Q3 EPS of $0.37, $0.01 better than the analyst estimate of $0.36. Revenue for the quarter came in at $137.2 million versus the consensus estimate of $138.5 million. GUIDANCE: Semtech sees Q4 2017 EPS of $0.33-$0.37. Semtech sees Q4 2017 revenue of $134-142 million.

Dollar General (NYSE: DG) 6% LOWER; reported Q3 EPS of $0.89, $0.04 worse than the analyst estimate of $0.93. Revenue for the quarter came in at $5.32 billion versus the consensus estimate of $5.37 billion. Comps fell 0.1 percent, versus a gain of 0.8 percent expected by analysts.

Cotiviti Holdings' (NYSE: COTV) 5.7% HIGHER; 10 million share secondary offering by holders was said to be pulled, according to Bloomberg, citing a person familiar with the matter.

La-Z-Boy (NYSE: LZB) 5.4% HIGHER; reported Q2 EPS of $0.42, $0.04 better than the analyst estimate of $0.38. Revenue for the quarter came in at $376.6 million versus the consensus estimate of $376.29 million. Raises dividend.

B/E Aerospace (NASDAQ: BEAV) 3.5% LOWER; Starboard said to push Rockwell Collins (NYSE: COL) to reconsider B/E deal, according to Bloomberg. Other top-25 investors are on board with Rockwell rejecting the B/E merger and want the company to explore a sale instead.

Fred's, Inc. (NASDAQ: FRED) 3% HIGHER; announced that it is rescheduling the release of its third quarter results and November sale

Rockwell Collins (NYSE: COL) 2.6% HIGHER; Starboard said to push Rockwell Collins (NYSE: COL) to reconsider B/E deal, according to Bloomberg. Other top-25 investors are on board with Rockwell rejecting the B/E merger and want the company to explore a sale instead.

Rexnord Corporation (NYSE: RXN) 2.3% LOWER; announced the commencement of an underwritten public offering of 7,000,000 depositary shares, each of which represents a 1/20th interest in a share of its Series A Mandatory Convertible Preferred Stock (“Mandatory Convertible Preferred Stock”). The underwriters of the offering have an option to buy up to 1,050,000 additional depositary shares to cover over-allotments.

Box (NYSE: BOX) 2.2% HIGHER; reported Q3 EPS of ($0.14), $0.05 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $102.8 million versus the consensus estimate of $100.64 million. GUIDANCE: Box sees Q4 2017 EPS of ($0.14)-($0.13), versus the consensus of ($0.16). Box sees Q4 2017 revenue of $108-109 million, versus the consensus of $108.8 million. Box sees FY2017 EPS of ($0.60)-($0.59), versus prior guidance of ($0.69)-($0.67) and the consensus of ($0.68). Box sees FY2017 revenue of $397-398 million, versus prior guidance of $394-396 million and the consensus of $395.2 million.

Synopsys (NASDAQ: SNPS) 2% LOWER; reported Q4 EPS of $0.77, in-line with the analyst estimate of $0.77. Revenue for the quarter came in at $633.7 million versus the consensus estimate of $628.41 million. GUIDANCE: Synopsys sees Q1 2017 EPS of $0.77-$0.80, versus the consensus of $0.76. Synopsys sees Q1 2017 revenue of $630-645 million, versus the consensus of $606.21 million. Synopsys sees FY2017 EPS of $3.16-$3.23. Synopsys sees FY2017 revenue of $2.57-2.6 billion.

Xencor, Inc. (Nasdaq: XNCR) 2% LOWER; announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Xencor expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares are being offered by Xencor. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Pure Storage, Inc. (NYSE: PSTG) 1% HIGHER; reported Q3 EPS of ($0.10), $0.05 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $197 million versus the consensus estimate of $192.36 million. GUIDANCE: Pure Storage, Inc. sees FY2017 revenue of $219-227 million, versus the consensus of $221.2 million. Non-GAAP gross margin in the range of 64% to 67%; Non-GAAP operating margin in the range of -9% to -5%.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers

Add Your Comment